Article
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.
The new microbiologica - 1 Jul 2016
Nozza Silvia, Pignataro Angela Rosa, Galli Laura, Svicher Valentina, Alteri Claudia, Boeri Enzo, Ripa Marco, Castagna Antonella, Sampaolo Michela, Clementi Massimo, Perno Carlo Federico, Lazzarin Adriano
Abstract excerpt
This study assessed the 48-week efficacy of an antiretroviral therapy including maraviroc following the assessment of co-receptor tropism by use of Geno2Pheno algorithm or the Trofile phenotypic assay in failing treatment-experienced HIV-1 patients. This was a multicenter, randomized, open-label, non-inferiority trial. Treatment-experienced subjects with HIV-RNA ≥500 copies/mL were randomized (1:1) to undergo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.